Isomorphic Labs has closed its $5 billion Series C funding round, the AI drug-discovery company announced on Tuesday. Co-led by Greenoaks and Sequoia Capital, the oversubscribed round will move its AI-designed drug candidates toward clinical trials and scale its drug-design engine.
The Round Closes
The round drew Andreessen Horowitz and several other new investors, with Alphabet making a significant investment and every existing backer returning, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its new valuation.
The close turns last week’s report into a done deal. Nine days ago this site reported that Isomorphic was seeking about $5 billion at a reported $50 billion valuation; the round is now confirmed, though the valuation remains undisclosed and the $50 billion figure was never confirmed by the company.
What the Money Buys
Isomorphic will use the money to advance IsoDDE, its proprietary drug-design engine, and to scale its pipeline of internal and partnered medicine candidates. It will also build out the global bioengineering infrastructure needed to take AI-designed drugs from simulation to patients.
The company says its programs have produced positive preclinical results in oncology and immunology, the first sign its engine can design drugs that work in living systems. It has struck deals with pharma giants Eli Lilly, Novartis and Johnson and Johnson to develop candidates together.
Our Read
This is the moment AI drug discovery has to prove itself. Designing molecules on a computer is now routine; the hard part is showing that candidates designed this way survive animal tests and human trials. Isomorphic’s preclinical results are encouraging, but no candidate has yet entered a trial.
The investor list is the strongest signal in the announcement. Greenoaks and Sequoia co-led, Andreessen Horowitz joined, and Alphabet put in more money — a vote from the parent company that spun Isomorphic out of DeepMind. Mirendil raised $1 billion in a Series A last week.
The valuation silence is worth noting. Bloomberg reported earlier this month that Isomorphic sought a $50 billion valuation, but the company disclosed no figure today. Private-market prices are not proof of value, and the real test is clinical data, not the next funding headline.
Why It Matters
Why it matters: Isomorphic is the flagship test of whether AI can design real medicines, not just predict protein shapes. If its candidates reach human trials and show results, the whole field gains credibility; if they stall, the $7.1 billion from its last two rounds buys time, not proof.
What to watch is the first trial filing. Isomorphic has named no candidate, no disease target and no trial date, so the next real milestone is a named drug entering human testing. Until then, the story is funding and promise, not medicine.
The funding also shows how AI’s biggest bets are shifting. Drug discovery joins agents, robotics and infrastructure as a destination for billion-dollar rounds, and Alphabet’s continued backing ties Isomorphic’s fate to the same ecosystem that produced AlphaFold and Gemini models.
Background
Background: Isomorphic was founded in 2021 as a spinout of Google DeepMind, building on the AlphaFold protein-folding breakthrough that won Demis Hassabis and John Jumper the Nobel Prize in chemistry. Hassabis left his role as DeepMind chief executive this year to focus on drug discovery.
Source: Isomorphic’s funding announcement and TechCrunch’s report.


0 Comments